美国食品及药物管理局(FDA)最近批准了阿目金和 Wyeth 药厂生产的类风湿关节炎针剂 Enbrel 的新剂型。此前这类针剂需要间隔3～4D 分两次注射,每次25mg,现在则只需要每周注射一次即可。Enbrel 是一种采用遗传工程技术制备的蛋白质,其作用机理是通过与肿瘤坏死因子(TNF)结合而使之失活,可用于治疗中度和严重类风湿关节炎和强直性脊柱炎等炎症,此次获准的新剂型还可用于治疗417岁的儿童及青少年患者。FDA The U.S. Food and Drug Administration (FDA) recently approved new formulations of rheumatoid arthritis injections Enbrel from Amur Kim and Wyeth. Prior to this type of injection need interval 3 ~ 4D injection twice, each time 25mg, now only need to be injected once a week. Enbrel is a genetically engineered protein whose mechanism of action is inactivated by binding to tumor necrosis factor (TNF) and is useful for the treatment of inflammation such as moderate and severe rheumatoid arthritis and ankylosing spondylitis, The approved new dosage form can also be used to treat 417-year-old children and adolescents. FDA